3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Status
Completed
2
Active not recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
3
Endocrine
1
Conditions
Breast Neoplasms
2
Neoplasms by Site
1
Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Breast Diseases
1
Advanced Metastatic Breast Cancer
1
Interventions
Trastuzumab
9
Paclitaxel
8
Capecitabine
8
trastuzumab deruxtecan
7
Fulvestrant
7
pertuzumab
5
eribulin
5
Gemcitabine
5
Cyclophosphamide
5
130-nm albumin-bound paclitaxel
5
Doxorubicin
4
Carboplatin
4
Ado-Trastuzumab Emtansine
4
sacituzumab govitecan
3
ribociclib
3
Vinorelbine
3
Epirubicin
3
Docetaxel
3
selpercatinib
2
pembrolizumab
2
palbociclib
2
olaparib
2
neratinib
2
larotrectinib
2
exemestane
2
capivasertib
2
abemaciclib
2
Letrozole
2
Fluorouracil
2
Anastrozole
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Has announcements
×
ribociclib
×
Breast
×
Clear all
NCT03701334
2026-04-01
NATALEE
Novartis
Phase 3
Active not recruiting
5,101 enrolled
1 FDA
NCT02278120
2024-03-12
MONALEESA-7
Novartis
Phase 3
Completed
672 enrolled
16 charts
1 FDA
NCT02422615
2023-11-30
MONALEESA-3
Novartis
Phase 3
Completed
726 enrolled
17 charts
1 FDA